Giant wins ArgiNox account

Share this article:

ArgiNox Pharmaceuticals, of Menlo Park, Ca named Giant Creative Strategy as the agency of record for their lead compound, tilarginine acetate. Tilarginine acetate is currently being studied in clinical trials for the treatment of cardiogenic shock. Giant will work with ArgiNox to develop an integrated scientific market preparation campaign, as well as naming and all branding and promotional materials for the product's impending launch.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.